Different safety profiles of first-line bendamustine-rituximab (BR), R-CHOP, and R-CVP in an open-label, randomized study of indolent non-Hodgkin lymphoma (NHL) and mantle cell lymphoma (MCL): The BRIGHT study.
David MacDonald
Consultant or Advisory Role - Lundbeck; Roche
Richard van der Jagt
Consultant or Advisory Role - Lundbeck; Teva
Honoraria - Celgene; Novartis; Roche
Research Funding - Celgene; Cell Therapeutics; Lundbeck; Roche; Teva
John M. Burke
Consultant or Advisory Role - Alexion Pharmaceuticals; Dendreon; Genomic Health; Seattle Genetics; Spectrum Pharmaceuticals
Research Funding - Genentech
Brad S. Kahl
Consultant or Advisory Role - Genentech; Teva
Research Funding - Genentech
Peter Wood
No relevant relationships to disclose
Tim E. Hawkins
No relevant relationships to disclose
Mark Hertzberg
No relevant relationships to disclose
Yiu-Lam Kwan
No relevant relationships to disclose
David Simpson
No relevant relationships to disclose
Michael Craig
No relevant relationships to disclose
Kathryn S. Kolibaba
Research Funding - Pharmacyclics
Samar Issa
No relevant relationships to disclose
Regina Clementi
Employment or Leadership Position - Teva
Stock Ownership - Teva
Doreen M. Hallman
Employment or Leadership Position - Teva
Mihaela C. Munteanu
Employment or Leadership Position - Teva
Stock Ownership - Teva
Ling Chen
Employment or Leadership Position - Teva
Stock Ownership - Teva
Ian Flinn
Research Funding - Teva